Cargando…
Energy Stress-Mediated Cytotoxicity in Tuberous Sclerosis Complex 2-Deficient Cells with Nelfinavir and Mefloquine Treatment
To find new anti-cancer drug therapies, we wanted to exploit homeostatic vulnerabilities within Tuberous Sclerosis Complex 2 (TSC2)-deficient cells with mechanistic target of rapamycin complex 1 (mTORC1) hyperactivity. We show that nelfinavir and mefloquine synergize to selectively evoke a cytotoxic...
Autores principales: | McCann, Henry D., Johnson, Charlotte E., Errington, Rachel J., Davies, D. Mark, Dunlop, Elaine A., Tee, Andrew R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210998/ https://www.ncbi.nlm.nih.gov/pubmed/30308940 http://dx.doi.org/10.3390/cancers10100375 |
Ejemplares similares
-
Correction: Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir–bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death
por: Johnson, Charlotte E., et al.
Publicado: (2019) -
Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells
por: Dunlop, Elaine A., et al.
Publicado: (2017) -
The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma
por: Besse, Lenka, et al.
Publicado: (2023) -
Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells
por: Brüning, Ansgar, et al.
Publicado: (2010) -
Activity of mefloquine and mefloquine derivatives against Echinococcus multilocularis
por: Rufener, Reto, et al.
Publicado: (2018)